Orexin-A and -B stimulate appetite and food intake in rats. Orexins and orexin receptors are present in the hypothalamus as well as the enteric nervous system, the pancreas and the gut. The presence of orexins in peripheral blood, however, has not yet been reported. To determine whether orexin-A is present in human plasma and is related to body weight, we measured plasma orexin-A and leptin levels in a population with a body mass index (BMI) range from 19.8 to 59 kg=m 2 . Plasma orexin-A levels correlated negatively and plasma leptin levels correlated positively with BMI. In obese and morbidly obese individuals, orexin-A levels were significantly lower and leptin levels were significantly higher when compared to normal. Our results support previous data suggesting that orexin-A acts also in a peripheral manner. The fact that lower levels of plasma orexin-A are present in obese individuals suggests that it is involved in the regulation of human energy metabolism.
Introduction
Orexin-A and -B are polypeptides that regulate appetite and food intake. 1, 2 Centrally administered orexin-A to rodents stimulates food intake, 1, 3 while anti-orexin-A antibodies have the reverse effect. 4 Peripherally administered orexin-A increases insulin secretion and results in increased blood glucose levels. 5 Orexins and orexin receptors are present in the hypothalamus as well as the enteric nervous system, the pancreas and the gut. 6 Leptin is another polypeptide important in regulating feeding behavior. 7 In non-fasting humans serum leptin levels strongly correlate with body fat content. 8 Since there is evidence that orexins can pass the bloodbrain barrier 9 and are expressed in peripheral tissues, we hypothesized that orexin-A is present in the human peripheral circulation and its levels would differ in individuals with increasing body mass index (BMI) and plasma leptin levels.
Fifteen morbidly obese individuals were admitted to the Surgical Department of the University Hospital Maastricht to undergo surgical treatment for morbid obesity and 23 healthy volunteers were matched for gender and age to get a study population with a BMI range from 19.8 to 59 kg=m 2 . All individuals were healthy according to history, clinical examination and routine laboratory findings and none had narcolepsy. The medical ethical committee of the University Hospital Maastricht approved the study and all subjects gave informed consent. Blood samples were collected in sterile EDTA tubes after overnight fast at the same time to prevent diurnal variations. Samples were set on ice immediately after collection. Plasma was separated by centrifugation at 1400 g for 10 min at 4 C. The supernatant was centrifuged at 2700 g for 10 min and aliquots were stored at 7 80 C. Orexin-A concentrations were measured in duplicate in extracted acidified plasma using C 18 SEP-columns, 1% TFA as wash buffer and 60% acetonitrile in 1% TFA as elution buffer. We used a commercially available human orexin-A RIA (Phoenix Pharmaceuticals, Mountain View, CA, USA). The assay makes use of polyclonal rabbit antibodies specific for human orexin-A and a goat -anti-rabbit antibody to separate bound and free fraction. The assay is calibrated with the kit standard of 1280 pg=ml. The lowest detectable concentration is 40 pg=ml. In the lower concentration range the coefficient of variation is 10%. The manufacturer states that there is no measurable cross-reactivity with the fragment 16 -33 of human orexin-A, with orexin-B, agouti-related protein amide (83 -132), neuropeptide-Y, a-MSH and human leptin. Leptin was measured using a commercially available human leptin ELISA kit (BioVendor, Brno, Czech Republic).
Statistical analysis was performed by one-way ANOVA for the orexin-A results. Since data were not normally distributed we used Kruskal -Wallis one-way ANOVA on Ranks for leptin. P-values less than 0.05 were considered statistically significant.
Plasma orexin-A levels ranged from 40 to 61.4 pg=ml and plasma leptin levels from 0.8 to 107.9 ng=ml. There was a significant decrease in plasma orexin levels with increasing BMI (r 2 ¼ 0.188, P ¼ 0.006), while plasma leptin levels significantly increased, as expected (r 2 ¼ 0.722, P < 0.0001; Figure  1 ). To investigate plasma orexin-A and leptin level changes in different grades of obesity, individuals were grouped according to the following WHO criteria: normal (BMI < 25 kg=m 2 ), n ¼ 10; overweight (BMI 25 -30 kg=m 2 ), n ¼ 8; obese (BMI 30 -40 kg=m 2 ), n ¼ 10; morbidly obese ( > 40 kg=m 2 ), n ¼ 10. Comparisons between groups for orexin-A were performed by one-way ANOVA. Significant difference was found for all groups (P ¼ 0.033). Pairwise multiple comparisons to normal group by Mann -Whitney rank sum test showed significantly lower (P < 0.01) orexin-A levels in the obese and morbidly obese group. The differences between groups for leptin were done with by KruskalWallis one-way ANOVA on ranks and were found to be highly significant (P < 0.0001). Pairwise multiple comparisons with normal group by Mann -Whitney rank sum test were significantly higher (P < 0.0001) in obese and morbidly obese groups. Neither orexin-A nor leptin in the overweight group differed from the normal group significantly ( Figure  2 ). Even when the study population was divided by male and female, the results remained unchanged (figure not shown).
Orexins and leptin are important counterparts in the regulatory network of energy homeostasis in animals, although it remains unclear whether their actions are equivalent in humans. It has been reported that orexin-A is present in the cerebrospinal fluid of healthy individuals and some narcoleptic patients. 10 It has, however, not yet been detected in human peripheral blood. Our data show that orexin-A is measurable in extracted plasma. Circulating orexin-A originates either from the hypothalamus via brain-to-blood transport or it is enterally produced and is, at least partially, released to the peripheral blood. Since orexin-A is co-produced with insulin in the pancreatic beta cells in guinea pigs and rats, 6 it is also conceivable that in humans, orexin-A may act as a hormone-like substance modulating the effects of insulin on food intake and glucose homeostasis. There is evidence that orexin-A and leptin act contraregulatory on feeding behavior in rodents. Chronic intraperitoneal administration of leptin results in a significant decrease in orexin-A mRNA levels in the hypothalamus, independently of its weight-reducing effect.
11 During fasting, when leptin levels drop, prepro-orexin mRNA is upregulated. 1 The fact that orexin-containing neurons express leptin receptor 12 supports the hypothesis of a central regulatory link between these two substances. It was recently reported that orexin-A plays a crucial role in the regulation of sleep-arousal. 10,13 -15 While orexin-A is not detectable in the central nervous system (CNS) in human and rodent narcolepsy, decreased leptin levels despite higher BMI are observed in narcoleptic patients. 15 In contrast, our results show, for non-narcoleptic humans, a decrease in orexin-A levels while BMI and leptin levels increase. It has yet to be determined whether this decrease of orexin-A is due to a negative feedback regulation of arousal and feeding behavior. It is also possible that the orexin-A leptin loop is different in narcoleptic patients. While we should be mindful of the complexity of energy homeostasis regulation and the limited knowledge about leptin action in humans, our data suggest that the regulatory routes are similar to those seen in healthy animals.
In conclusion, the fact that orexin-A is present in human plasma supports previous data suggesting that it is a substance that may also act in a peripheral manner. Its biological Each column represents the mean AE s.e.m. *P < 0.001; **P < 0.0001 compared with the normal group by Mann -Whitney rank sum test.
Decreased plasma orexin-A levels JA Adam et al role in the peripheral blood is yet unclear. The fact that plasma orexin-A levels are decreased in obese individuals implicates that it is involved, in a manner yet unknown, in the regulation of human energy metabolism.
